Caristo Diagnostics Completes Series A Financing and Welcomes New CEO to Advance Ground-Breaking AI Technology for Cardiac Disease Detection
Summary
Caristo will use the capital to advance its CaRi-Heart\xae technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets. "Caristo continues to make tremendous progress in the delivery of its innovative technology to help healthcare professionals predict and prevent future heart attacks and ultimately save millions of lives around the world. CaRi-Hearts AI algorithms allow trained health professionals to obtain measures of coronary inflammation from routine cardiac computed tomography angiography (CCTA) scans by using Caristos Fat Attenuation Index (FAI) technology. This partnership enables OSE to work with the brightest academic minds tackling the worlds toughest challenges and guarantees unrivalled access to their scientific research. It applies advanced AI algorithms to routine cardiac CT scans to visualize and quantify coronary inflammation, which is the previously invisible root cause of the disease.